# Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07106892/  
OnCo record `nct07106892` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX43 Dose 1; in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07106892 by Shanghai Henlius Biotech, with 60 participants planned, started 2025-09-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: HLX43 Dose 1;, HLX43 Dose 2; and HLX43 Dose 3;.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07106892
- Phase: 2
- Setting: Phase II, Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07106892: https://clinicaltrials.gov/study/NCT07106892

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct07106892.json